Danaher Q1 2025 Earnings

- Net earnings: 954 million dollars
- GAAP earnings per share: 1.32 dollars (compared to 1.45 dollars in Q1 2024)
- Adjusted (non-GAAP) earnings per share: 1.88 dollars (compared to 1.92 dollars in Q1 2024)
- Revenue: 5.74 billion dollars, down 1.0 percent year-over-year
- Core revenue (non-GAAP): flat year-over-year
- Free cash flow: 1.06 billion dollars, down from 1.45 billion dollars in Q1 2024
- Operating cash flow: 1.3 billion dollars

Segment performance (core sales growth, non-GAAP):

- Biotechnology: up 7.0 percent
- Life sciences: down 4.0 percent
- Diagnostics: down 1.5 percent

Outlook:

- Q2 2025 core revenue growth: expected low-single digits
- Full year 2025 core revenue growth: approximately 3 percent
- Full year 2025 adjusted earnings per share guidance: 7.60 to 7.75 dollars

CEO commentary:

Rainer M. Blair stated that Danaher exceeded expectations in Q1 2025, benefiting from continued momentum in bioprocessing and stronger-than-expected respiratory demand in molecular diagnostics. Despite a dynamic macroeconomic backdrop, the company’s execution, portfolio strength, and financial position remain key differentiators.